Skip to main
NHI

NHI Stock Forecast & Price Target

NHI Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

National Health Investors Inc. has raised its normalized funds from operations (NFFO) estimates for 2025 to $4.80 per share, reflecting a positive revision driven by a strong performance in Q2 2025 and an optimistic outlook from management. Additionally, the company's 2026 FFO estimate has also been increased to $5.03 per share, surpassing the consensus estimate while indicating anticipated year-over-year growth rates of 5.3% for 2025 and 4.8% for 2026. These upward adjustments in financial forecasts suggest a robust operational performance and future growth potential, contributing to a favorable outlook for the stock.

Bears say

The analysis indicates that National Health Investors Inc. faces a negative outlook primarily due to anticipated lower earnings growth over the next few years, which stems from a combination of accretive acquisition activities and potential operational issues among its operators. Additionally, the company could experience underperformance if the rent reset for NHC does not meet investor expectations, along with risks associated with deferred rent collections and challenges faced by operators, particularly in light of potential pandemic-related disruptions. These factors collectively suggest a cautious financial environment for National Health Investors, impacting overall revenue and profitability prospects.

NHI has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of National Health Investors and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About National Health Investors (NHI) Forecast

Analysts have given NHI a Buy based on their latest research and market trends.

According to 5 analysts, NHI has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $86.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $86.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

National Health Investors (NHI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.